These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33871588)

  • 1. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.
    Bolli R; Solankhi M; Tang XL; Kahlon A
    Cardiovasc Res; 2022 Mar; 118(4):951-976. PubMed ID: 33871588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
    Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).
    Mathiasen AB; Qayyum AA; Jørgensen E; Helqvist S; Fischer-Nielsen A; Kofoed KF; Haack-Sørensen M; Ekblond A; Kastrup J
    Eur Heart J; 2015 Jul; 36(27):1744-53. PubMed ID: 25926562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure.
    Westerdahl DE; Chang DH; Hamilton MA; Nakamura M; Henry TD
    Expert Opin Biol Ther; 2016 Sep; 16(9):1163-9. PubMed ID: 27376188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit
    Bolli R; Hare JM; March KL; Pepine CJ; Willerson JT; Perin EC; Yang PC; Henry TD; Traverse JH; Mitrani RD; Khan A; Hernandez-Schulman I; Taylor DA; DiFede DL; Lima JAC; Chugh A; Loughran J; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Moyé L; Ebert RF; Simari RD;
    Circ Res; 2018 Jun; 122(12):1703-1715. PubMed ID: 29703749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.
    Mathiasen AB; Qayyum AA; Jørgensen E; Helqvist S; Kofoed KF; Haack-Sørensen M; Ekblond A; Kastrup J
    Eur J Heart Fail; 2020 May; 22(5):884-892. PubMed ID: 31863561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
    Patel AN; Henry TD; Quyyumi AA; Schaer GL; Anderson RD; Toma C; East C; Remmers AE; Goodrich J; Desai AS; Recker D; DeMaria A;
    Lancet; 2016 Jun; 387(10036):2412-21. PubMed ID: 27059887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design.
    Bartunek J; Davison B; Sherman W; Povsic T; Henry TD; Gersh B; Metra M; Filippatos G; Hajjar R; Behfar A; Homsy C; Cotter G; Wijns W; Tendera M; Terzic A
    Eur J Heart Fail; 2016 Feb; 18(2):160-8. PubMed ID: 26662998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges.
    Tongers J; Losordo DW; Landmesser U
    Eur Heart J; 2011 May; 32(10):1197-206. PubMed ID: 21362705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
    Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
    Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).
    Paitazoglou C; Bergmann MW; Vrtovec B; Chamuleau SAJ; van Klarenbosch B; Wojakowski W; Michalewska-Włudarczyk A; Gyöngyösi M; Ekblond A; Haack-Sørensen M; Jaquet K; Vrangbaek K; Kastrup J;
    Eur J Heart Fail; 2019 Aug; 21(8):1032-1041. PubMed ID: 30790396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of bone marrow- and adipose tissue-derived mesenchymal stem cell transplantation on myocardial remodelling in the rat model of ischaemic heart failure.
    Karpov AA; Uspenskaya YK; Minasian SM; Puzanov MV; Dmitrieva RI; Bilibina AA; Anisimov SV; Galagudza MM
    Int J Exp Pathol; 2013 Jun; 94(3):169-77. PubMed ID: 23560418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?
    Sanina C; Hare JM
    Circ Res; 2015 Jul; 117(3):229-33. PubMed ID: 26185208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study.
    Kastrup J; Haack-Sørensen M; Juhl M; Harary Søndergaard R; Follin B; Drozd Lund L; Mønsted Johansen E; Ali Qayyum A; Bruun Mathiasen A; Jørgensen E; Helqvist S; Jørgen Elberg J; Bruunsgaard H; Ekblond A
    Stem Cells Transl Med; 2017 Nov; 6(11):1963-1971. PubMed ID: 28880460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure.
    Perin EC; Borow KM; Silva GV; DeMaria AN; Marroquin OC; Huang PP; Traverse JH; Krum H; Skerrett D; Zheng Y; Willerson JT; Itescu S; Henry TD
    Circ Res; 2015 Aug; 117(6):576-84. PubMed ID: 26148930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
    Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
    Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications.
    Lipinski MJ; Luger D; Epstein SE
    Handb Exp Pharmacol; 2017; 243():329-353. PubMed ID: 28382469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy.
    Ichim TE; Solano F; Brenes R; Glenn E; Chang J; Chan K; Riordan NH
    Reprod Biomed Online; 2008 Jun; 16(6):898-905. PubMed ID: 18549704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort.
    Raval AN; Johnston PV; Duckers HJ; Cook TD; Traverse JH; Altman PA; Dhingra R; Hematti P; Borrello I; Anderson RD; Pepine CJ
    Int J Cardiol; 2021 Mar; 326():131-138. PubMed ID: 33091520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure　- What Is the Best Source?
    Kobayashi K; Suzuki K
    Circ J; 2018 Aug; 82(9):2222-2232. PubMed ID: 30089767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.